SLC6A1

Genomenon Partners with Three Rare Disease Foundations to Advance Precision Drug Development

Retrieved on: 
Tuesday, November 29, 2022

ANN ARBOR, Mich., Nov. 29, 2022 /PRNewswire-PRWeb/ -- Genomenon Inc., an AI-driven genomics company, announced a partnership with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect. Genomenon will collaborate with the foundations and their pharma partners, delivering comprehensive genomic data on their diseases of focus with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.

Key Points: 
  • Genomenon will collaborate with the foundations and their pharma partners, delivering comprehensive genomic data on their diseases of focus with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.
  • Genomenon is partnering with COMBINEDBrain, SynGAP, and SLC-6A1 Connect to provide that essential information to ensure the best chance of success.
  • Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer.
  • Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.

Invitae and Simons Searchlight Partner to Accelerate Research through Data Sharing

Retrieved on: 
Monday, September 12, 2022

SAN FRANCISCO, Sept. 12, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a collaboration with Simons Searchlight, an international research program with a goal of accelerating research and improving lives for people with rare genetic neurodevelopmental disorders. This partnership will connect two sets of data – the longitudinal clinical data extracted from medical records through Invitae's Ciitizen, a patient-consented, digital natural history data platform and patient reported outcomes and biospecimens collected by Simons Searchlight. The partnership breaks down data silos and provides a rich and deep dataset that will help accelerate research for rare neurodevelopmental diseases.

Key Points: 
  • The partnership breaks down data silos and provides a rich and deep dataset that will help accelerate research for rare neurodevelopmental diseases.
  • "Joining forces with Invitae is incredibly powerful for patients with rare diseases," said Jennifer Tjernagel, M.S., senior project manager at Simons Searchlight, Simons Foundation.
  • Charlene Son Rigby, president and co-founder of STXBP1 Foundation shared, "We are thrilled to partner with Invitae and Simons Searchlight on this initiative.
  • The relationship allowed consenting patients to link their de-identified Invitae Ciitizen data with the Simons Searchlight database to accelerate understanding of patients with STXBP1 disorder.

ProActive Solutions Celebrates 25 Years by Giving Back

Retrieved on: 
Tuesday, October 19, 2021

MISSION, Kan., Oct. 19, 2021 /PRNewswire/ --ProActive Solutions, one of the leading IT solutions providers in Kansas City celebrated their 25 years in business by giving $2500 to five charitable organizations.

Key Points: 
  • MISSION, Kan., Oct. 19, 2021 /PRNewswire/ --ProActive Solutions, one of the leading IT solutions providers in Kansas City celebrated their 25 years in business by giving $2500 to five charitable organizations.
  • ProActive Solutions celebrated their 25 years in business in Kansas by giving $2500 to five charitable organizations.
  • During the check presentation ceremony, Kimberly Fry, Director of Marketing and Events at ProActive Solutions said, "ProActive Solutions is proud to be a company that cares about the community where it has its roots.
  • Many of our employees live and work close to our headquarters in Mission, Kansas and they power our passion to design solutions for our customers."